Skip to content

Health Evaluation of Mushrooms withVitamin D2

Health Evaluation of Mushrooms withVitamin D2

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05716698
Enrollment
36
Registered
2023-02-08
Start date
2022-04-15
Completion date
2022-06-01
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy

Brief summary

Although Taiwan has plenty of sunshine, the intake of vitamin D and the concentration of 25(OH)D in the blood are low. Ingestion of mushrooms and extracts rich in D2 can increase the nutritional source of vitamin D. The purpose of this study is to evaluate the intake of D2 mushrooms and extracts in humans to achieve the effective concentration of 25(OH)D in the serum and recommendations for health improvement.

Detailed description

The subjects were divided into 3 groups: no mushroom intervention, intervention with D2 10ug Pleurotus citrinopileatus after bio-optics optimization (low dose group) or intervention with D2 100ug Pleurotus citrinopileatus after bio-optics optimization (high dose group). The low-dose group took D2 10ug per day, and the high-dose group received D2 100ug per day for a total of 4 weeks.

Interventions

DIETARY_SUPPLEMENTPleurotus citrinopileatus after bio-optics (10 ug group)

The participants took D2 10ug per day for a total of 4 weeks.

DIETARY_SUPPLEMENTPleurotus citrinopileatus after bio-optics (100 ug group)

The participants took D2 100ug per day for a total of 4 weeks.

Sponsors

Taipei Medical University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
20 Years to 60 Years
Healthy volunteers
Yes

Inclusion criteria

1\. Healthy human

Exclusion criteria

1. Any acute disease, such as infection, stroke, myocardial infarction or major surgery within three months, upper or lower gastrointestinal bleeding, blood pressure, and poor blood sugar control will be excluded. 2. Chronic diseases, such as malignant tumors, infection with human immunodeficiency virus (HIV) and related diseases, liver cirrhosis, or those with liver function exceeding 3 times the normal value (more than 120 IU/L), renal function (Cr) more than 2.5 mg /dl, chronic anemia (Hb \<9 g/dl), metabolic diseases except diabetes (such as thyroid/parathyroid dysfunction), and those who have undergone abdominal surgery to cause intestinal sticking are excluded. 3. Women who are pregnant or breastfeeding will be excluded. 4. Those who use steroids, supplements with vitamin D-containing dietary supplements and hormones will be excluded. 5. Those with blood 25(OH)D concentration \> 30 ng/ml will be excluded. 6. Those who are unwilling to fill out the consent form and refuse the questionnaire survey.

Design outcomes

Primary

MeasureTime frameDescription
Change from baseline in 25OHD at week 4Baseline and week 4The participants' blood was taken to analyze the concentration of 25OHD to compare the changes between baseline and 4 weeks later. 25OHD concentration standard is: 25OHD \< 20 ng/ml: deficiency 20 ng/ml \< 25OHD \< 30 ng/ml: Insufficiency 25OHD \> 30 ng/ml: Normal

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026